Triple-negative breast cancer: Advancements in characterization and treatment approach

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 1, 2016, Pages 59-69

  Hurvitz, Sara ^a   Mead, Monica ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Chemotherapy; Subtype; Triple negative

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BRAP PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

AGE DISTRIBUTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; PREVENTION AND CONTROL; SURVIVAL RATE; TRENDS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

AGE DISTRIBUTION; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84952983419     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000239     Document Type: Review

References (101)

1. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23:7350-7360.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
3. Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triplenegative breast cancer. Breast Cancer Res Treat 2009; 115:423-428.
4. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006; 12:1533-1539.
5. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 2007; 109:1721-1728.
6. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482-1485.
7. Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to 'triple-negative' breast cancer in Ashkenazi women. Breast Cancer Res Treat 2011; 129:185-190.
8. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7:134.
9. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14:1368-1376.
10. Narod SA, Dent RA, Foulkes WD. CCR 20th Anniversary Commentary: triple-negative breast cancer in 2015-still in the ballpark. Clin Cancer Res 2015; 21:3813-3814.
11. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123:236-240.
12. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
13. Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19:5533-5540.
14. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-819.
15. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010; 16:6159- 6168.
16. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26:778-785.
17. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-1281.
18. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119:551-558.
19. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (Gepar- Sixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014; 15:747- 756.
20. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13-21.
21. Tung NM, Winer EP. Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. J Clin Oncol 2015; 33:969- 971.
22. Yamaguchi R, Tanaka M, Yano A, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 2012; 43:1688-1694.
23. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-113.
24. Issa-Nummer Y, Darb-Esfahani S, Loibl S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer: A substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013; 8:e79775.
25. West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13:R126.
26. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol 2012; 30:1996-2004.
27. Vicente Valero NO. A randomized phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000 cited 9/16/15. URL of the record NLM Identifier: NCT02488967.
28. Park BW. A phase III trial of carboplatin as adjuvant chemotherapy versus observation in triple negative breast cancer with pathologic residual cancer after neoadjuvant chemotherapy: POST-neo adjuvant study. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/16/15]. URL of the record NLM Identifier: NCT01752686.
29. Kern P, Kalisch A, von Minckwitz G, et al. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: A multicentric analysis of rates of pathologic complete response and survival. J Chemother 2015; 59:387-394.
30. Kaklamani VG, Jeruss JS, Hughes E, et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat 2015; 151:629-638.
31. Masuda N, Higaki K, Takano T, et al. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother Pharmacol 2014; 74:229-238.
32. Cancello G, Bagnardi V, Sangalli C, et al. Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer. Clin Breast Cancer 2015; 15:259-265.
33. Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triplenegative metastatic breast cancer: A systematic review and meta-analysis. Core Evid 2014; 9:1-11.
34. Ma CX, Ellis MJ, Petroni GR, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 2013; 137:483-492.
35. Liu M, Mo QG, Wei CY, et al. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett 2013; 5:983-991.
36. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010; 16:53-61.
37. Tutt A, Ellis P, Kilburn L, et al. Abstract S3-01: the TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res 2015; 75 (9 Suppl); S3-01.
38. Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy with biomarker assessment in metastatic triple-negative breast cancer. e 2015; 33:1902-1909.
39. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16:5222-5232.
40. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triplenegative breast cancer: implications for therapy. Cancer 2015; 121:8-16.
41. Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107:1776-1782.
42. Popova T, Manié E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72:5454-5462.
43. Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, nonrandomized trial of cisplatin chemotherapy in patients with BRCA1- positive metastatic breast cancer. Breast Cancer Res 2012; 14:R110.
44. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008; 108:289-296.
45. Chew HK, Doroshow JH, Frankel P, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009; 27:2163-2169.
46. Xu B, Jiang Z, Kim SB, et al. Biweekly gemcitabine-paclitaxel, gemcitabinecarboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: A phase II randomized selection trial. Breast Cancer 2011; 18:203-212.
47. Nagourney RA, Link JS, Blitzer JB, et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18:2245-2249.
48. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2:521-530.
49. van Moorsel CJ, Kroep JR, Pinedo HM, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999; 10:441-448.
50. Zhang J, Wang Z, Hu X, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer 2015; 136:204-211.
51. Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16:436-446.
52. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102:3738-3743.
53. Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-2984.
54. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
55. Chen XS, Yuan Y, Garfield DH, et al. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: A meta-analysis. PLoS One 2014; 9:e108405.
56. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14:933-942.
57. Miller K, Dang CT. Bevacizumab, HER2-negative itato, Cooperative bcFrfE, Oncology Group E5103. J Clin Oncol; 32, 500.
58. Center MDAC. Women's triple-negative first-line study: A phase II trial of liposomal doxorubicin, bevacizumab and temsirolimus (DAT) in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/17/15]. URL of the record NLM Identifier: NCT02456857.
59. Institute TNC. Biomarker discovery randomized phase IIb trial with carboplatin- cyclophosphamide versus paclitaxel with or without bevacizumab as first-line treatment in advanced triple negative breast cancer. In: Clinical- Trialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/17/15]. URL of the record NLM Identifier: NCT01898117.
60. Group HOR. Weekly paclitaxel-carboplatin plus bevacizumab as first line therapy for patients with triple negative (ER-, PR-, HER2-) metastatic breast cancer. A multicenter phase I-II study. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT00691379.
61. Roche H-L. Open-label study of bevacizumab (avastin) and taxane monotherapy for the first-line treatment of patients with advanced triple negative breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT01094184.
62. Rutgers TSUoNJ. A phase II trial of doxil, carboplatin and bevacizumab in triple negative previously untreated metastatic breast cancer. In: Clinical- Trialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT00608972.
63. Roche H-L. Multi centre, pilot phase II trial assessing the efficacy and safety of bevacizumabgemcitabinecarboplatin as first line treatment for patients diagnosed with triple negative metastatic breast cancer. In: Clinical- Trialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT01201265.
64. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med 2012; 366:1382-1392.
65. Telli ML, Jensen KC, Vinayak S, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumorbased measure of genomic instability: PrECOG 0105. J Clin Oncol 2015; 33:1895-1901.
66. O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32:3840-3847.
67. Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 2012; 18:1655-1662.
68. Licht SCH, Li Z. Mechanism of action of iniparib: stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. Mol Cancer Ther 2011; 10 (Suppl):a226.
69. Anders C, Deal AM, Abramson V, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat 2014; 146:557- 566.
70. O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32:3840-3847.
71. AbbVie. A randomized, placebo-controlled, double-blind, phase 3 study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage triple negative breast cancer (TNBC). In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT02032277.
72. Birmingham UoAa. An open label, pilot study of veliparib (ABT-888) and lapatinib (Tykerb) in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT02158507.
73. Institute D-FC. Phase I study of the oral PI3kinase inhibitor BKM120 or BYL719 and the oral PARP inhibitor olaparib in patients with recurrent triple negative breast cancer or high grade serous ovarian cancer. In: Clinical- Trialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT01623349.
74. Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in nonbasal triple negative breast cancers and determines novel therapeutic options. PLoS One 2014; 9:e88525.
75. Mrklic I, Pogorelic Z, Capkun V, Tomic S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 2013; 115:344-348.
76. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen- sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596-1605.
77. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65:467-479.
78. Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013; 19:5505-5512.
79. Traina T, Miller K, Yardley DA, et al. Results from a phase 2 study of enzalutamide an androgen receptor (AR) inhibitor, in advanced AR triple-negative breast cancer (TNBC). J Clin Oncol 33, 2015 (suppl; abstr 1003). 2015; 2015 ASCO Annual Meeting. (Abstract Number 1003).
80. Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014; 16:406.
81. Cuenca-Lopez MD, Montero JC, Morales JC, et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014; 14:302.
82. Center V-IC. A phase Ib/II trial of taselisib (GDC-0032), a PI3K inhibitor, in combination with enzalutamide in patients with androgen receptor positive triple negative metastatic breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/16/15]. URL of the record NLM Identifier: NCT02457910.
83. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395-399.
84. Rodon J, Brana I, Siu LL, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014; 32:670-681.
85. Group SBCR. A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/1/15]. URL of the record NLM Identifier: NCT01629615.
86. Liu H, Zang C, Schefe JH, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 2011; 31:2713-2722.
87. Singh J, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014; 16:R32.
88. Group SBCR. A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/2/15]. URL of the record NLM Identifier: NCT02531932.
89. Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancerdagger. Ann Oncol 2014; 25:1122-1127.
90. System TMH. Neoadjuvant phase II study of everolimus plus cisplatin in triple negative breast cancer patients with residual disease after standard chemotherapy. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/2/15]. URL of the record NLM Identifier: NCT01931163.
91. Homet Moreno B, Ribas A. Antiprogrammed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 2015; 112:1421-1427.
92. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triplenegative breast cancer. Cancer Immunol Res 2014; 2:361-370.
93. Nanda RCL, Dees EC, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. 2014. [Meeting abstracts] San Antonio Breast Cancer Symposium.
94. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Meeting Abstract. 2015; American Association for Cancer Research.
95. Corp MSD. A phase II clinical trial of pembrolizumab (MK-3475) as monotherapy for metastatic triple-negative breast cancer (mTNBC) - (KEYNOTE-086). In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000. URL of the record NLM Identifier: NCT02447003.
96. Corporation C. A phase 1, open-Label, multicenter, safety study of nivolumab (BMS-936558) in combination with nab-paclitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage IIIB/IV non-small cell lung cancer or nab-paclitaxel in recurrent metastatic breast cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/15/15]. URL of the record NLM Identifier: NCT02309177.
97. Institute TNC. Adaptive phase II randomized noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: TONIC-trial. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/2/15]. URL of the record NLM Identifier: NCT02499367.
98. Bryan Schneider M. A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer: Hoosier Oncology Group BRE12-158. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/1/15]. URL of the record NLM Identifier: NCT02101385.
99. Shusen W. A phase III randomized controlled trial of prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000; [9/15/15]. URL of the record NLM Identifier: NCT02448576.
100. Takahashi R, Toh U, Iwakuma N, et al. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res 2014; 16:R70.
101. Xu J, Prosperi JR, Choudhury N, et al. beta-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One 2015; 10:e0117097.